Lionel Gillot
Research Subjects
Research Interests
Lionel Gillot has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Vega-Gálvez
Food Engineering Department, Universidad de La Serena, Av. Raúl Bitrán 1305, La Serena 1700000, Chile
1 shared publication Casey Peavler
Holy Cross Health, 4725 N Federal Hwy, Fort Lauderdale, FL 33308, USA
1 shared publication- Enrique A. Martinez Mosqueira
Oasis Santé, Medical Center, 30700 Uzès, France
1 shared publication - Fabrice Joulia
Laboratoire Jeunesse-Activité Physique et Sportive-Santé (J-AP2S), Univ Toulon, 83041 Toulon, France
1 shared publication - Pierrick Martinez
Toulon University, France
1 shared publication - William Burgess Grant
Sunlight, Nutrition and Health Research Center, San Francisco, CA, USA
1 shared publication
Latest Publications
- Open Access
- 28 June 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (7) , 809
The Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice
Supplements are widely perceived as safe and beneficial; yet in oncology, this assumption is questionable. Clinical trials over the past few decades have often produced disappointing results, raising a critical question: are these agents used correctly, or could they inadvertently cause harm? This review examines supplements frequently used in cancer care—such as oral vitamin C, berberine, N-acetylcysteine, vitamin D, vitamin E, melatonin, polyphenols, alpha-lipoic acid, selenium, and coenzyme Q10—which can act as tumor suppressors or promoters depending on dose, route, and disease stage. We examine their dual antioxidant and pro-oxidant properties, revealing that therapeutic outcomes are shaped not only by the molecule itself, but also by bioavailability, dosing thresholds, and the tumor redox environment. Building on these insights, we propose that four factors may be considered to guide clinical use: ensure that anticancer effects are not overshadowed by antioxidant activity, achieve sufficient bioavailability, confirm pro-oxidant concentrations where possible, and prioritize supplements that target the respiration-supported non-OxPhos pathways. By framing supplements as context-dependent redox modulators rather than universally beneficial agents, this review provides a mechanistically grounded framework for informing future research and safer, more effective integrative oncology strategies.
- 28 June 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (7) , 809
Open AccessThe Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice
Supplements are widely perceived as safe and beneficial; yet in oncology, this assumption is questionable. Clinical trials over the past few decades have often produced disappointing results, raising a critical question: are these agents used correctly, or could they inadvertently cause harm? This review examines supplements frequently used in cancer care—such as oral vitamin C, berberine, N-acetylcysteine, vitamin D, vitamin E, melatonin, polyphenols, alpha-lipoic acid, selenium, and coenzyme Q10—which can act as tumor suppressors or promoters depending on dose, route, and disease stage. We examine their dual antioxidant and pro-oxidant properties, revealing that therapeutic outcomes are shaped not only by the molecule itself, but also by bioavailability, dosing thresholds, and the tumor redox environment. Building on these insights, we propose that four factors may be considered to guide clinical use: ensure that anticancer effects are not overshadowed by antioxidant activity, achieve sufficient bioavailability, confirm pro-oxidant concentrations where possible, and prioritize supplements that target the respiration-supported non-OxPhos pathways. By framing supplements as context-dependent redox modulators rather than universally beneficial agents, this review provides a mechanistically grounded framework for informing future research and safer, more effective integrative oncology strategies.